The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical development of the bispecific PSMAxCD3 antibody CC-1.
 
Christopher Hackenbruch
No Relationships to Disclose
 
Jonas S. Heitmann
Travel, Accommodations, Expenses - Synimmune
 
Juliane S. Walz
Research Funding - GlaxoSmithKline; Roche Pharma AG
Patents, Royalties, Other Intellectual Property - CoVac-1 peptide cocktail, Application number: PCT/EP 20 190 070.1; Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar HCCand other cancers, Application number: EP 2121472; SARS-CoV-2 CD8+ und CD4+ T cell epitopes, Application number: PCT/EP 20 169 047.6
 
Birgit Federmann
No Relationships to Disclose
 
Martin Pflügler
No Relationships to Disclose
 
Richard F. Schlenk
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo Pharmaceutical; Jazz Pharmaceuticals
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo Pharmaceutical; Pfizer; PharmaMar; Recordati; Roche Pharma AG
Travel, Accommodations, Expenses - Daiichi Sankyo Pharmaceutical
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Janssen; Merck; MSD
Consulting or Advisory Role - Immunicon; Janssen; MSD
Speakers' Bureau - MSD
Patents, Royalties, Other Intellectual Property - Cyclin A1-targeted T-cell immunotherapy for cancer, AU2017206216B2
Travel, Accommodations, Expenses - Janssen; Merck; Pfizer
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Amgen; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Janssen
 
Christopher Darr
Honoraria - Janssen
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Gundram Jung
Stock and Other Ownership Interests - CureVac; Immatics
Consulting or Advisory Role - Cullinan Oncology
Patents, Royalties, Other Intellectual Property - An optimized ACE2 fusion protein with improved activity against SARS-CoV-2 variants (ACE2 fusion protein)EP 22198499.0
 
Helmut R. Salih
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Novartis; Pfizer; Philogen; Synimmune
Research Funding - ABL Bio
Patents, Royalties, Other Intellectual Property - Inventor on several patents in the field of caner immunotherapy
(OPTIONAL) Uncompensated Relationships - TWYCE GmbH